JP2013515729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515729A5 JP2013515729A5 JP2012546092A JP2012546092A JP2013515729A5 JP 2013515729 A5 JP2013515729 A5 JP 2013515729A5 JP 2012546092 A JP2012546092 A JP 2012546092A JP 2012546092 A JP2012546092 A JP 2012546092A JP 2013515729 A5 JP2013515729 A5 JP 2013515729A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- fluoro
- pyridin
- aminocyclohexylamino
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyrazol-4-yl Chemical group 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 22
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 claims description 4
- BSLMYSMDBCERIF-LLVKDONJSA-N (2r)-2-[[7-fluoro-4-(5-methylfuran-2-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=C(C)O1 BSLMYSMDBCERIF-LLVKDONJSA-N 0.000 claims description 3
- FGNXLVIOOATBPG-CYBMUJFWSA-N (2r)-2-[(7-fluoro-3-oxo-4-pyrazolo[1,5-a]pyridin-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl)amino]-4-methylpentanamide Chemical compound C1=NN2C=CC=CC2=C1C1=C(C(=O)NC2)C2=C(F)C(N[C@H](CC(C)C)C(N)=O)=N1 FGNXLVIOOATBPG-CYBMUJFWSA-N 0.000 claims description 2
- JJLZPPPPMCXNMR-SNVBAGLBSA-N (2r)-2-[(7-fluoro-3-oxo-4-thiophen-2-yl-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl)amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=CS1 JJLZPPPPMCXNMR-SNVBAGLBSA-N 0.000 claims description 2
- CIGKEEPNOLLPRK-LLVKDONJSA-N (2r)-2-[(7-fluoro-3-oxo-4-thiophen-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl)amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C=1C=CSC=1 CIGKEEPNOLLPRK-LLVKDONJSA-N 0.000 claims description 2
- XXXHWWOKBAILHE-CQSZACIVSA-N (2r)-2-[[4-(1-benzofuran-3-yl)-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C1=CC=C2C(C=3N=C(C(=C4CNC(=O)C4=3)F)N[C@H](CC(C)C)C(N)=O)=COC2=C1 XXXHWWOKBAILHE-CQSZACIVSA-N 0.000 claims description 2
- KDUTVDRIWILGKD-CYBMUJFWSA-N (2r)-2-[[4-(1-cyclopropylpyrazol-4-yl)-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C(=C1)C=NN1C1CC1 KDUTVDRIWILGKD-CYBMUJFWSA-N 0.000 claims description 2
- HZWOOJCFQCXZBU-LLVKDONJSA-N (2r)-2-[[4-(4-cyanothiophen-2-yl)-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC(C#N)=CS1 HZWOOJCFQCXZBU-LLVKDONJSA-N 0.000 claims description 2
- JTHONIAHQFULQN-LLVKDONJSA-N (2r)-2-[[4-(5-cyanothiophen-2-yl)-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=C(C#N)S1 JTHONIAHQFULQN-LLVKDONJSA-N 0.000 claims description 2
- XRGNIAJRYCAFFV-SNVBAGLBSA-N (2r)-2-[[4-[1-(difluoromethyl)pyrazol-4-yl]-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C=1C=NN(C(F)F)C=1 XRGNIAJRYCAFFV-SNVBAGLBSA-N 0.000 claims description 2
- MBLSIKKPQOPSNQ-SECBINFHSA-N (2r)-2-[[7-fluoro-3-oxo-4-(1,3-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CN=CS1 MBLSIKKPQOPSNQ-SECBINFHSA-N 0.000 claims description 2
- BAWQWVQBXIDYII-LLVKDONJSA-N (2r)-2-[[7-fluoro-4-(1-methylpyrazol-4-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C=1C=NN(C)C=1 BAWQWVQBXIDYII-LLVKDONJSA-N 0.000 claims description 2
- ORFPWEPWRPUBLL-GFCCVEGCSA-N (2r)-2-[[7-fluoro-4-(1-methylpyrazol-4-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-n,4-dimethylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(=O)NC)=NC=1C=1C=NN(C)C=1 ORFPWEPWRPUBLL-GFCCVEGCSA-N 0.000 claims description 2
- KUOCWDDVPWWSKP-SNVBAGLBSA-N (2r)-2-[[7-fluoro-4-(2-methyl-1,3-thiazol-5-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CN=C(C)S1 KUOCWDDVPWWSKP-SNVBAGLBSA-N 0.000 claims description 2
- UZPROEIMLUTQLE-LLVKDONJSA-N (2r)-2-[[7-fluoro-4-(4-methylthiophen-2-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC(C)=CS1 UZPROEIMLUTQLE-LLVKDONJSA-N 0.000 claims description 2
- NHPYANOEODOMDL-LLVKDONJSA-N (2r)-2-[[7-fluoro-4-(5-methylthiophen-2-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=C(C)S1 NHPYANOEODOMDL-LLVKDONJSA-N 0.000 claims description 2
- GEKOIFFWMZQBDJ-SNVBAGLBSA-N (2r)-2-[[7-fluoro-4-(furan-2-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=CO1 GEKOIFFWMZQBDJ-SNVBAGLBSA-N 0.000 claims description 2
- NTOQJLGNEKUUHL-LLVKDONJSA-N (2r)-2-[[7-fluoro-4-(furan-3-yl)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C=1C=COC=1 NTOQJLGNEKUUHL-LLVKDONJSA-N 0.000 claims description 2
- IZLQWNFMZKOICR-OAHLLOKOSA-N (2r)-4-methyl-2-[[4-(3-methylsulfonylanilino)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]pentanamide Chemical compound N=1C(N[C@H](CC(C)C)C(N)=O)=CC=2CNC(=O)C=2C=1NC1=CC=CC(S(C)(=O)=O)=C1 IZLQWNFMZKOICR-OAHLLOKOSA-N 0.000 claims description 2
- UXHMPPWAKKPFSX-UHFFFAOYSA-N 6-[(2-amino-3,3,3-trifluoropropyl)amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(NCC(N)C(F)(F)F)N=2)=C1 UXHMPPWAKKPFSX-UHFFFAOYSA-N 0.000 claims description 2
- ZSWNYKLXHIEKMU-VIFPVBQESA-N 6-[(3s)-3-aminopyrrolidin-1-yl]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N2C[C@@H](N)CC2)=C(F)C2=C1C(=O)NC2 ZSWNYKLXHIEKMU-VIFPVBQESA-N 0.000 claims description 2
- PNRLUYPLNOPXDL-MLGOLLRUSA-N 6-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-4-(1-cyclopropylpyrazol-4-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1CCC(F)(F)[C@H](N)[C@@H]1NC1=NC(C2=CN(N=C2)C2CC2)=C(C(=O)NC2)C2=C1F PNRLUYPLNOPXDL-MLGOLLRUSA-N 0.000 claims description 2
- FCVUZQDOZYEBBN-RHSMWYFYSA-N 6-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](C(F)(F)CCC3)N)N=2)=C1 FCVUZQDOZYEBBN-RHSMWYFYSA-N 0.000 claims description 2
- HYXZKQNQMCBUBO-NOZJJQNGSA-N 6-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-4-[1-(difluoromethyl)pyrazol-4-yl]-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1CCC(F)(F)[C@H](N)[C@@H]1NC1=NC(C2=CN(N=C2)C(F)F)=C(C(=O)NC2)C2=C1F HYXZKQNQMCBUBO-NOZJJQNGSA-N 0.000 claims description 2
- XOTZDLZZONOQJK-QMTHXVAHSA-N 6-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](C(F)(F)CCC2)N)=C(F)C2=C1C(=O)NC2 XOTZDLZZONOQJK-QMTHXVAHSA-N 0.000 claims description 2
- IBRCKLBEVCEQHD-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-benzofuran-3-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C=2C3=CC=CC=C3OC=2)=C(C(=O)NC2)C2=C1F IBRCKLBEVCEQHD-LSDHHAIUSA-N 0.000 claims description 2
- NLHMXERGXZJVSA-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-benzothiophen-3-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C=2C3=CC=CC=C3SC=2)=C(C(=O)NC2)C2=C1F NLHMXERGXZJVSA-LSDHHAIUSA-N 0.000 claims description 2
- RBAFUBZTBXELTG-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-cyclopropylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C2=CN(N=C2)C2CC2)=CC2=C1C(=O)NC2 RBAFUBZTBXELTG-LSDHHAIUSA-N 0.000 claims description 2
- FFDWUYASOWCJJD-UONOGXRCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-ethylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(CC)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=CC2=C1C(=O)NC2 FFDWUYASOWCJJD-UONOGXRCSA-N 0.000 claims description 2
- BIRMRVDNUGHXQF-QWHCGFSZSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=CC2=C1C(=O)NC2 BIRMRVDNUGHXQF-QWHCGFSZSA-N 0.000 claims description 2
- LOFXHRXBASKCPJ-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1h-indazol-6-ylamino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C3NN=CC3=CC=2)=CC2=C1C(=O)NC2 LOFXHRXBASKCPJ-LSDHHAIUSA-N 0.000 claims description 2
- BCQZEYKBUNMINW-DTWKUNHWSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(2-amino-1,3-thiazol-5-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C=2SC(N)=NC=2)=C(C(=O)NC2)C2=C1F BCQZEYKBUNMINW-DTWKUNHWSA-N 0.000 claims description 2
- UITJPHZNGQVUHM-JKSUJKDBSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 UITJPHZNGQVUHM-JKSUJKDBSA-N 0.000 claims description 2
- UOBUBZWFFCOCAE-DLBZAZTESA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridine-7-carbonitrile Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(C#N)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 UOBUBZWFFCOCAE-DLBZAZTESA-N 0.000 claims description 2
- ZHCYNQAPDHKDTK-ZWKOTPCHSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)-7-(2-methylpyrazol-3-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(=C(N[C@H]3[C@H](CCCC3)N)N=2)C=2N(N=CC=2)C)=C1 ZHCYNQAPDHKDTK-ZWKOTPCHSA-N 0.000 claims description 2
- JCKXIUBFRBOHRV-DLBZAZTESA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)-7-prop-2-enoyl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(C(=O)C=C)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 JCKXIUBFRBOHRV-DLBZAZTESA-N 0.000 claims description 2
- JHMLNISRSWFRDP-JKSUJKDBSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylsulfonylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CS(=O)(=O)C1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 JHMLNISRSWFRDP-JKSUJKDBSA-N 0.000 claims description 2
- VHBREDNCCOLHGT-JKSUJKDBSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(4-fluoro-3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 VHBREDNCCOLHGT-JKSUJKDBSA-N 0.000 claims description 2
- WELNIAICBOVSLC-WDEREUQCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[1-(difluoromethyl)pyrazol-4-yl]-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C2=CN(N=C2)C(F)F)=C(C(=O)NC2)C2=C1F WELNIAICBOVSLC-WDEREUQCSA-N 0.000 claims description 2
- QGIZHMIRSUGPQA-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-chloro-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(Cl)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 QGIZHMIRSUGPQA-LSDHHAIUSA-N 0.000 claims description 2
- XLLZLRGOFITEPW-NWDGAFQWSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-1,1-dimethyl-4-(1-methylpyrazol-4-yl)-2h-pyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2(C)C XLLZLRGOFITEPW-NWDGAFQWSA-N 0.000 claims description 2
- DDFCHGYRRJNLDH-CLGJWYQZSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-1-methyl-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1NC(=O)C(C(=N2)C3=CN(C)N=C3)=C1C(F)=C2N[C@@H]1CCCC[C@@H]1N DDFCHGYRRJNLDH-CLGJWYQZSA-N 0.000 claims description 2
- XYDQHRTVTJCMOX-WDEREUQCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-(2-methyl-1,3-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound S1C(C)=NC=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 XYDQHRTVTJCMOX-WDEREUQCSA-N 0.000 claims description 2
- QSLDDROANYSPRV-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(F)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 QSLDDROANYSPRV-LSDHHAIUSA-N 0.000 claims description 2
- HPFJFZGOUINWHT-NWDGAFQWSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-(4-methylthiophen-2-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CSC(C=2C=3C(=O)NCC=3C(F)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 HPFJFZGOUINWHT-NWDGAFQWSA-N 0.000 claims description 2
- JVWJCIFIORGGQG-NWDGAFQWSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-(5-methylthiophen-2-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound S1C(C)=CC=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 JVWJCIFIORGGQG-NWDGAFQWSA-N 0.000 claims description 2
- NHGIXSAEPXILDH-QWHCGFSZSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-imidazo[1,2-a]pyridin-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C=2N3C=CC=CC3=NC=2)=C(C(=O)NC2)C2=C1F NHGIXSAEPXILDH-QWHCGFSZSA-N 0.000 claims description 2
- BRUXXXWLFWMGMH-UONOGXRCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-pyrazolo[1,5-a]pyridin-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C2=C3C=CC=CN3N=C2)=C(C(=O)NC2)C2=C1F BRUXXXWLFWMGMH-UONOGXRCSA-N 0.000 claims description 2
- NKPIDKJVHYGCQT-WDEREUQCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-thiophen-2-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C=2SC=CC=2)=C(C(=O)NC2)C2=C1F NKPIDKJVHYGCQT-WDEREUQCSA-N 0.000 claims description 2
- ZVLVGTYXHIBEQV-NWDGAFQWSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-thiophen-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C2=CSC=C2)=C(C(=O)NC2)C2=C1F ZVLVGTYXHIBEQV-NWDGAFQWSA-N 0.000 claims description 2
- URAIYDRYCJOIAK-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-iodo-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(I)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 URAIYDRYCJOIAK-LSDHHAIUSA-N 0.000 claims description 2
- AJASROCNLFYWOD-DLBZAZTESA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-methyl-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C(C)=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 AJASROCNLFYWOD-DLBZAZTESA-N 0.000 claims description 2
- ZBJMLPUPNJBUBV-LSDHHAIUSA-N 6-[[(1r,2s)-2-aminocyclopentyl]amino]-4-(3-methylsulfonylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CS(=O)(=O)C1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](CCC3)N)N=2)=C1 ZBJMLPUPNJBUBV-LSDHHAIUSA-N 0.000 claims description 2
- CNLZGMLAACBFPD-CQSZACIVSA-N 6-[[(2r)-2-amino-3-ethoxypropyl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N=1C(NC[C@@H](N)COCC)=CC=2CNC(=O)C=2C=1NC1=CC=CC(C)=C1 CNLZGMLAACBFPD-CQSZACIVSA-N 0.000 claims description 2
- VFYIMFKQSSVIKO-GFCCVEGCSA-N 6-[[(2r)-2-amino-3-ethoxypropyl]amino]-7-fluoro-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C=12C(=O)NCC2=C(F)C(NC[C@@H](N)COCC)=NC=1NC1=CC=CC(C)=C1 VFYIMFKQSSVIKO-GFCCVEGCSA-N 0.000 claims description 2
- PTVFGLINHKTHNO-LLVKDONJSA-N 6-[[(2r)-2-amino-3-methoxypropyl]amino]-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N=1C(NC[C@@H](N)COC)=CC=2CNC(=O)C=2C=1C=1C=NN(C)C=1 PTVFGLINHKTHNO-LLVKDONJSA-N 0.000 claims description 2
- MQRNMOQGZFFVSQ-CYBMUJFWSA-N 6-[[(2r)-2-amino-3-methoxypropyl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N=1C(NC[C@@H](N)COC)=CC=2CNC(=O)C=2C=1NC1=CC=CC(C)=C1 MQRNMOQGZFFVSQ-CYBMUJFWSA-N 0.000 claims description 2
- NGAWMQNSOMDIGI-GFCCVEGCSA-N 6-[[(2r)-2-amino-3-methoxypropyl]amino]-4-(3-methylanilino)-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridine-7-carbonitrile Chemical compound C=12C(=O)NCC2=C(C#N)C(NC[C@@H](N)COC)=NC=1NC1=CC=CC(C)=C1 NGAWMQNSOMDIGI-GFCCVEGCSA-N 0.000 claims description 2
- DZSPBFLSHHMSRH-LLVKDONJSA-N 6-[[(2r)-2-amino-3-methoxypropyl]amino]-7-fluoro-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C=12C(=O)NCC2=C(F)C(NC[C@@H](N)COC)=NC=1NC1=CC=CC(C)=C1 DZSPBFLSHHMSRH-LLVKDONJSA-N 0.000 claims description 2
- HTFZCIZUCWDECV-UONOGXRCSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-(1-benzofuran-3-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C=2C3=CC=CC=C3OC=2)=C(C(=O)NC2)C2=C1F HTFZCIZUCWDECV-UONOGXRCSA-N 0.000 claims description 2
- QJXYPBJTYPNXKY-NWDGAFQWSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](COCC2)N)=CC2=C1C(=O)NC2 QJXYPBJTYPNXKY-NWDGAFQWSA-N 0.000 claims description 2
- QJZVPOAVHOGBBL-LSDHHAIUSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](COCC3)N)N=2)=C1 QJZVPOAVHOGBBL-LSDHHAIUSA-N 0.000 claims description 2
- BLKFBGHXROJYIY-DTWKUNHWSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-(5-chlorothiophen-2-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C=2SC(Cl)=CC=2)=C(C(=O)NC2)C2=C1F BLKFBGHXROJYIY-DTWKUNHWSA-N 0.000 claims description 2
- RYADIWBTHCLJOG-VHSXEESVSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-[1-(difluoromethyl)pyrazol-4-yl]-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C2=CN(N=C2)C(F)F)=C(C(=O)NC2)C2=C1F RYADIWBTHCLJOG-VHSXEESVSA-N 0.000 claims description 2
- YOJNDLCTGCQRMX-DTWKUNHWSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(1,3-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C=2SC=NC=2)=C(C(=O)NC2)C2=C1F YOJNDLCTGCQRMX-DTWKUNHWSA-N 0.000 claims description 2
- MZQLFFCEMFAOCC-WDEREUQCSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](COCC2)N)=C(F)C2=C1C(=O)NC2 MZQLFFCEMFAOCC-WDEREUQCSA-N 0.000 claims description 2
- GPYXWRFZMKWDCJ-VHSXEESVSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(2-methyl-1,3-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound S1C(C)=NC=C1C1=NC(N[C@H]2[C@H](COCC2)N)=C(F)C2=C1C(=O)NC2 GPYXWRFZMKWDCJ-VHSXEESVSA-N 0.000 claims description 2
- SVZXXGPSWXRXKK-VHSXEESVSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(3-methyl-1,2-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound S1N=C(C)C=C1C1=NC(N[C@H]2[C@H](COCC2)N)=C(F)C2=C1C(=O)NC2 SVZXXGPSWXRXKK-VHSXEESVSA-N 0.000 claims description 2
- DWTOIXQXYXFUSJ-WDEREUQCSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(4-methylthiophen-2-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CSC(C=2C=3C(=O)NCC=3C(F)=C(N[C@H]3[C@H](COCC3)N)N=2)=C1 DWTOIXQXYXFUSJ-WDEREUQCSA-N 0.000 claims description 2
- UACMJLWTOXKNPO-WDEREUQCSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-(5-methylthiophen-2-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound S1C(C)=CC=C1C1=NC(N[C@H]2[C@H](COCC2)N)=C(F)C2=C1C(=O)NC2 UACMJLWTOXKNPO-WDEREUQCSA-N 0.000 claims description 2
- RDXHNSBRBBUIST-DTWKUNHWSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-[4-(trifluoromethyl)imidazol-1-yl]-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(N2C=C(N=C2)C(F)(F)F)=C(C(=O)NC2)C2=C1F RDXHNSBRBBUIST-DTWKUNHWSA-N 0.000 claims description 2
- QXAVMZBGVPCVJW-QWHCGFSZSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-pyrazolo[1,5-a]pyridin-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C2=C3C=CC=CN3N=C2)=C(C(=O)NC2)C2=C1F QXAVMZBGVPCVJW-QWHCGFSZSA-N 0.000 claims description 2
- CRXNLSFJLAXVGI-VHSXEESVSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-thiophen-2-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C=2SC=CC=2)=C(C(=O)NC2)C2=C1F CRXNLSFJLAXVGI-VHSXEESVSA-N 0.000 claims description 2
- RAGCQARLABKAAH-WDEREUQCSA-N 6-[[(3r,4r)-3-aminooxan-4-yl]amino]-7-fluoro-4-thiophen-3-yl-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1COCC[C@H]1NC1=NC(C2=CSC=C2)=C(C(=O)NC2)C2=C1F RAGCQARLABKAAH-WDEREUQCSA-N 0.000 claims description 2
- YXSQBQNEFNOEBB-CABCVRRESA-N 6-[[(3r,4r)-4-aminooxan-3-yl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@@H]3[C@@H](CCOC3)N)N=2)=C1 YXSQBQNEFNOEBB-CABCVRRESA-N 0.000 claims description 2
- YUGJNJDUJMQFPH-UONOGXRCSA-N 6-[[(3s,4r)-4-aminooxolan-3-yl]amino]-4-(3-methylanilino)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3C=C(N[C@H]3[C@H](COC3)N)N=2)=C1 YUGJNJDUJMQFPH-UONOGXRCSA-N 0.000 claims description 2
- RLXNNTQQSLSLQA-UHFFFAOYSA-N 7-fluoro-4,6-bis(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(C2=CN(C)N=C2)=C(F)C2=C1C(=O)NC2 RLXNNTQQSLSLQA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- MJHOMTRKVMKCNE-NWDGAFQWSA-N mivavotinib Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 MJHOMTRKVMKCNE-NWDGAFQWSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- OVAPNXCAPWCXDI-SECBINFHSA-N (2r)-2-[[7-fluoro-3-oxo-4-(1,2-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(N[C@H](CC(C)C)C(N)=O)=NC=1C1=CC=NS1 OVAPNXCAPWCXDI-SECBINFHSA-N 0.000 claims 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- HCKPQVQJKBSTHP-UHFFFAOYSA-N 1h-isothiochromene Chemical compound C1=CC=C2CSC=CC2=C1 HCKPQVQJKBSTHP-UHFFFAOYSA-N 0.000 claims 1
- UHMBAIDDVAGJCG-UONOGXRCSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-cyclopropylpyrazol-4-yl)-7-fluoro-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound N[C@H]1CCCC[C@H]1NC1=NC(C2=CN(N=C2)C2CC2)=C(C(=O)NC2)C2=C1F UHMBAIDDVAGJCG-UONOGXRCSA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- IEEGLSJYUPRDCU-UHFFFAOYSA-N O1CC=CC=C1.NC1COCCC1 Chemical compound O1CC=CC=C1.NC1COCCC1 IEEGLSJYUPRDCU-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- KNQKVFLNQXDRCP-UONOGXRCSA-N N[C@@H]1[C@@H](CCCC1)NC=1N=C(C2=C(N1)CNC2=O)C=2C=C(C=CC2)C Chemical compound N[C@@H]1[C@@H](CCCC1)NC=1N=C(C2=C(N1)CNC2=O)C=2C=C(C=CC2)C KNQKVFLNQXDRCP-UONOGXRCSA-N 0.000 description 2
- OPDRSBKBDWZHLE-UHFFFAOYSA-N 2-(2-aminoethylamino)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(NCCN)N=2)=C1 OPDRSBKBDWZHLE-UHFFFAOYSA-N 0.000 description 1
- FVJOLSXHWBIDLU-UHFFFAOYSA-N 2-(3-aminopiperidin-1-yl)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(N=2)N2CC(N)CCC2)=C1 FVJOLSXHWBIDLU-UHFFFAOYSA-N 0.000 description 1
- FMWOGANRUCFFAR-UHFFFAOYSA-N 2-(3-aminopropyl)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(CCCN)N=2)=C1 FMWOGANRUCFFAR-UHFFFAOYSA-N 0.000 description 1
- IUAAVEWTWOMZRH-UHFFFAOYSA-N 2-(3-aminopyrrolidin-1-yl)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(N=2)N2CC(N)CC2)=C1 IUAAVEWTWOMZRH-UHFFFAOYSA-N 0.000 description 1
- IQDYWYLYQGLIFS-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1CN(CC)CCN1C(N=C1NC=2C=C(C)C=CC=2)=NC2=C1C(=O)NC2 IQDYWYLYQGLIFS-UHFFFAOYSA-N 0.000 description 1
- JRTCSSCKQPIELQ-UHFFFAOYSA-N 2-(cyclohexylamino)-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(NC3CCCCC3)N=2)=C1 JRTCSSCKQPIELQ-UHFFFAOYSA-N 0.000 description 1
- MOVFMVAKMICKFT-UHFFFAOYSA-N 2-[(2-amino-2-methylpropyl)amino]-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(NCC(C)(C)N)N=2)=C1 MOVFMVAKMICKFT-UHFFFAOYSA-N 0.000 description 1
- QSCCXSUVCSPPAD-UHFFFAOYSA-N 2-[2-aminoethyl(methyl)amino]-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N=1C(N(CCN)C)=NC=2CNC(=O)C=2C=1NC1=CC=CC(C)=C1 QSCCXSUVCSPPAD-UHFFFAOYSA-N 0.000 description 1
- RPXDYJAYIKDXOW-WBVHZDCISA-N 2-[[(1r,2s)-2-(dimethylamino)cyclohexyl]amino]-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CN(C)[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C(C)C=CC=2)=NC2=C1C(=O)NC2 RPXDYJAYIKDXOW-WBVHZDCISA-N 0.000 description 1
- UCFAUSQCVJRLNA-LSDHHAIUSA-N 2-[[(1r,2s)-2-(methylamino)cyclohexyl]amino]-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CN[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C(C)C=CC=2)=NC2=C1C(=O)NC2 UCFAUSQCVJRLNA-LSDHHAIUSA-N 0.000 description 1
- HWJURIDHSVIDIZ-NWDGAFQWSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1,5-dimethylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(C)C(C)=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 HWJURIDHSVIDIZ-NWDGAFQWSA-N 0.000 description 1
- ZELQCQBWASDXFO-DLBZAZTESA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-benzylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C2=CN(CC=3C=CC=CC=3)N=C2)=NC2=C1C(=O)NC2 ZELQCQBWASDXFO-DLBZAZTESA-N 0.000 description 1
- LJGKKZRBLSULPA-NWDGAFQWSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-ethylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(CC)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 LJGKKZRBLSULPA-NWDGAFQWSA-N 0.000 description 1
- RFPLNLGVRFCQMM-WDEREUQCSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-methylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 RFPLNLGVRFCQMM-WDEREUQCSA-N 0.000 description 1
- BXSVNWLQXNREPJ-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1-propylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(CCC)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 BXSVNWLQXNREPJ-QWHCGFSZSA-N 0.000 description 1
- QCTFMLFWYRDMCM-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1h-indazol-6-ylamino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C3NN=CC3=CC=2)=NC2=C1C(=O)NC2 QCTFMLFWYRDMCM-QWHCGFSZSA-N 0.000 description 1
- RVAKPWBSEAKFQD-GXTWGEPZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1h-indol-2-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C=2NC3=CC=CC=C3C=2)=NC2=C1C(=O)NC2 RVAKPWBSEAKFQD-GXTWGEPZSA-N 0.000 description 1
- PIMALXKGEPZTHN-DTWKUNHWSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(1h-pyrazol-5-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C=2NN=CC=2)=NC2=C1C(=O)NC2 PIMALXKGEPZTHN-DTWKUNHWSA-N 0.000 description 1
- RZJUCOGLHVRVMU-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-chloroanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C(Cl)C=CC=2)=NC2=C1C(=O)NC2 RZJUCOGLHVRVMU-QWHCGFSZSA-N 0.000 description 1
- YOWCQOMDWAKWJH-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-fluoroanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1NC=2C=C(F)C=CC=2)=NC2=C1C(=O)NC2 YOWCQOMDWAKWJH-QWHCGFSZSA-N 0.000 description 1
- VPNLOOYVNORYBV-UONOGXRCSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 VPNLOOYVNORYBV-UONOGXRCSA-N 0.000 description 1
- NANBZQDYUFCFNV-LSDHHAIUSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-(3-methylanilino)spiro[6h-pyrrolo[3,4-d]pyrimidine-7,1'-cyclopropane]-5-one Chemical compound CC1=CC=CC(NC=2C3=C(C4(CC4)NC3=O)N=C(N[C@H]3[C@H](CCCC3)N)N=2)=C1 NANBZQDYUFCFNV-LSDHHAIUSA-N 0.000 description 1
- FHXRJVORQQEROL-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[1-(2-methoxyethyl)pyrazol-4-yl]-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(CCOC)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 FHXRJVORQQEROL-QWHCGFSZSA-N 0.000 description 1
- NBJRGKFKJYKCFT-UONOGXRCSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[1-(2-methylpropyl)pyrazol-4-yl]-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound C1=NN(CC(C)C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=NC2=C1C(=O)NC2 NBJRGKFKJYKCFT-UONOGXRCSA-N 0.000 description 1
- LQWXROUOCBFBHT-JKSUJKDBSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[1-(4-fluorophenyl)pyrazol-4-yl]-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C2=CN(N=C2)C=2C=CC(F)=CC=2)=NC2=C1C(=O)NC2 LQWXROUOCBFBHT-JKSUJKDBSA-N 0.000 description 1
- YQMYCUZXRUTFMQ-NWDGAFQWSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-imidazo[1,2-a]pyridin-3-yl-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C=2N3C=CC=CC3=NC=2)=NC2=C1C(=O)NC2 YQMYCUZXRUTFMQ-NWDGAFQWSA-N 0.000 description 1
- JGNFRPZOVOEHCX-QWHCGFSZSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-phenyl-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound N[C@H]1CCCC[C@H]1NC(N=C1C=2C=CC=CC=2)=NC2=C1C(=O)NC2 JGNFRPZOVOEHCX-QWHCGFSZSA-N 0.000 description 1
- OVAPNXCAPWCXDI-UHFFFAOYSA-N 2-[[7-fluoro-3-oxo-4-(1,2-thiazol-5-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]-4-methylpentanamide Chemical compound C=12C(=O)NCC2=C(F)C(NC(CC(C)C)C(N)=O)=NC=1C1=CC=NS1 OVAPNXCAPWCXDI-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KOFXCODJJPXPSU-UHFFFAOYSA-N 4-(3-methylanilino)-2-(1-methylpyrazol-4-yl)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(N=2)C2=CN(C)N=C2)=C1 KOFXCODJJPXPSU-UHFFFAOYSA-N 0.000 description 1
- FONZMRYOGGHENU-UHFFFAOYSA-N 4-(3-methylanilino)-2-(pyrrolidin-2-ylmethylamino)-6,7-dihydropyrrolo[3,4-d]pyrimidin-5-one Chemical compound CC1=CC=CC(NC=2C=3C(=O)NCC=3N=C(NCC3NCCC3)N=2)=C1 FONZMRYOGGHENU-UHFFFAOYSA-N 0.000 description 1
- QOEGYIMEVZZRCM-JTQLQIEISA-N 6-[(3s)-3-aminopiperidin-1-yl]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N2C[C@@H](N)CCC2)=C(F)C2=C1C(=O)NC2 QOEGYIMEVZZRCM-JTQLQIEISA-N 0.000 description 1
- MVSNAIBOHYBGEN-VHSXEESVSA-N 6-[[(1r,2s)-2-amino-4,4-difluorocyclopentyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CC(F)(F)C2)N)=C(F)C2=C1C(=O)NC2 MVSNAIBOHYBGEN-VHSXEESVSA-N 0.000 description 1
- KNTKCQSJBGJFFV-SECBINFHSA-N 6-[[(2r)-2-amino-3-methoxypropyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one Chemical compound C=12C(=O)NCC2=C(F)C(NC[C@@H](N)COC)=NC=1C=1C=NN(C)C=1 KNTKCQSJBGJFFV-SECBINFHSA-N 0.000 description 1
- NOQFXYBVFFJTBP-UHFFFAOYSA-N CC1=CC(NC(N=C2)=NC(CN3)=C2C3=O)=CC=C1 Chemical compound CC1=CC(NC(N=C2)=NC(CN3)=C2C3=O)=CC=C1 NOQFXYBVFFJTBP-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1cc(Nc(nc(N[C@](CCCC2)[C@@]2N)nc2CN3)c2C3=*)ccc1 Chemical compound Cc1cc(Nc(nc(N[C@](CCCC2)[C@@]2N)nc2CN3)c2C3=*)ccc1 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- CYSGPDJTJKFWEG-CVEARBPZSA-N tert-butyl n-[(1s,2r)-2-[[4-(1-ethylpyrazol-4-yl)-7-fluoro-3-oxo-1,2-dihydropyrrolo[3,4-c]pyridin-6-yl]amino]cyclohexyl]carbamate Chemical compound C1=NN(CC)C=C1C1=NC(N[C@H]2[C@H](CCCC2)NC(=O)OC(C)(C)C)=C(F)C2=C1C(=O)NC2 CYSGPDJTJKFWEG-CVEARBPZSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28996909P | 2009-12-23 | 2009-12-23 | |
| US61/289,969 | 2009-12-23 | ||
| US38696410P | 2010-09-27 | 2010-09-27 | |
| US61/386,964 | 2010-09-27 | ||
| PCT/US2010/061146 WO2011079051A1 (en) | 2009-12-23 | 2010-12-17 | Fused heteroaromatic pyrrolidinones as syk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239677A Division JP5968983B2 (ja) | 2009-12-23 | 2014-11-27 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515729A JP2013515729A (ja) | 2013-05-09 |
| JP2013515729A5 true JP2013515729A5 (enExample) | 2014-02-06 |
| JP5658274B2 JP5658274B2 (ja) | 2015-01-21 |
Family
ID=43618073
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546092A Active JP5658274B2 (ja) | 2009-12-23 | 2010-12-17 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2014239677A Expired - Fee Related JP5968983B2 (ja) | 2009-12-23 | 2014-11-27 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2016133849A Active JP6196710B2 (ja) | 2009-12-23 | 2016-07-06 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2017158005A Pending JP2018009017A (ja) | 2009-12-23 | 2017-08-18 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2018235779A Pending JP2019056000A (ja) | 2009-12-23 | 2018-12-17 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2020107416A Pending JP2020164537A (ja) | 2009-12-23 | 2020-06-23 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2022083170A Pending JP2022110135A (ja) | 2009-12-23 | 2022-05-20 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239677A Expired - Fee Related JP5968983B2 (ja) | 2009-12-23 | 2014-11-27 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2016133849A Active JP6196710B2 (ja) | 2009-12-23 | 2016-07-06 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2017158005A Pending JP2018009017A (ja) | 2009-12-23 | 2017-08-18 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2018235779A Pending JP2019056000A (ja) | 2009-12-23 | 2018-12-17 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2020107416A Pending JP2020164537A (ja) | 2009-12-23 | 2020-06-23 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
| JP2022083170A Pending JP2022110135A (ja) | 2009-12-23 | 2022-05-20 | Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン |
Country Status (42)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
| SG181857A1 (en) * | 2009-12-23 | 2012-07-30 | Takeda Pharmaceutical | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| JP6001048B2 (ja) * | 2011-03-28 | 2016-10-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | チアゾロピリミジン化合物 |
| US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| EP2900243A4 (en) | 2012-09-27 | 2016-04-13 | Portola Pharm Inc | BICYCLIC OXA LACTAM KINASE HEMMER |
| EP2900639B1 (en) * | 2012-09-27 | 2017-08-16 | Portola Pharmaceuticals, Inc. | Bicyclic dihydropyridone kinase inhibitors |
| WO2014071109A1 (en) | 2012-11-01 | 2014-05-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014151386A1 (en) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US20140377258A1 (en) | 2013-05-30 | 2014-12-25 | Infinity Pharmaceuticals, Inc. | Treatment Of Cancers Using PI3 Kinase Isoform Modulators |
| AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
| PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| ES2921874T3 (es) * | 2014-02-28 | 2022-09-01 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
| CN113620958A (zh) | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| US10245262B2 (en) | 2014-04-01 | 2019-04-02 | The University Of Queensland | Immunological reagents and uses therefor |
| WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| KR20170090476A (ko) * | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
| PL3233857T3 (pl) * | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
| ES2930585T3 (es) | 2015-02-27 | 2022-12-19 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
| US10023571B2 (en) * | 2015-09-02 | 2018-07-17 | Nimbus Lakshimi, Inc. | TYK2 inhibitors and uses thereof |
| PH12018500554B1 (en) | 2015-09-14 | 2024-01-24 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| WO2017205801A1 (en) * | 2016-05-27 | 2017-11-30 | Takeda Pharmaceutical Company Limited | Combination of immunotherapy agents and spleen tyrosine kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20190971A1 (es) | 2016-06-13 | 2019-07-09 | Glaxosmithkline Ip Dev Ltd | Compuestos quimicos |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| JP2019520419A (ja) * | 2016-07-13 | 2019-07-18 | 武田薬品工業株式会社 | 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用 |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| CA3036384A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| ES2906205T3 (es) * | 2017-06-14 | 2022-04-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhibidor de Syk y método de uso para el mismo |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| US11174254B2 (en) | 2017-09-28 | 2021-11-16 | Yangtze River Pharmaceutical Group Co., Ltd. | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| SG11202002475TA (en) * | 2017-10-19 | 2020-04-29 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
| WO2019088039A1 (en) | 2017-10-30 | 2019-05-09 | Takeda Pharmaceutical Company Limited | Treatment of acute myeloid leukemia |
| CN111295384B (zh) * | 2018-10-10 | 2022-08-12 | 江苏豪森药业集团有限公司 | 双环类衍生物抑制剂、其制备方法和应用 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| JP7608166B2 (ja) | 2019-01-11 | 2025-01-06 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
| JP2022521413A (ja) * | 2019-02-22 | 2022-04-07 | クロノス バイオ インコーポレイテッド | Ｓｙｋ阻害剤としての縮合ピラジンの固体形態 |
| WO2020187267A1 (zh) * | 2019-03-18 | 2020-09-24 | 上海海雁医药科技有限公司 | Btk抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022048551A1 (zh) * | 2020-09-01 | 2022-03-10 | 上海海雁医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 |
| CN115698005B (zh) * | 2020-12-18 | 2024-02-06 | 山东轩竹医药科技有限公司 | 稠环类AhR抑制剂 |
| US20240174662A1 (en) * | 2021-02-01 | 2024-05-30 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| JP2024540296A (ja) * | 2021-11-04 | 2024-10-31 | レデックス・ファーマ・リミテッド | 線維症 |
| CN114907992B (zh) | 2022-05-18 | 2023-06-16 | 塔里木大学 | 拮抗植物病原菌的菌株c11及其应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63107966A (ja) | 1986-05-22 | 1988-05-12 | Fujisawa Pharmaceut Co Ltd | ピリミジン誘導体 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1054004B1 (en) * | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
| WO1999032479A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
| EP1184376B1 (en) | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
| FR2796946A1 (fr) | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| EP1250128A2 (en) | 1999-12-16 | 2002-10-23 | Alcon, Inc. | Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| EP1244668B1 (en) | 2000-01-07 | 2006-04-05 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
| AU2001232271A1 (en) | 2000-02-14 | 2001-08-20 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| AU2003286895A1 (en) | 2002-11-05 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
| EP1610793A2 (en) | 2003-03-25 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| CA2523126A1 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US20050182061A1 (en) | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
| JP4768628B2 (ja) * | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| WO2005056524A2 (en) | 2003-12-09 | 2005-06-23 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US8057815B2 (en) * | 2004-04-19 | 2011-11-15 | Portola Pharmaceuticals, Inc. | Methods of treatment with Syk inhibitors |
| JP2008511659A (ja) | 2004-09-01 | 2008-04-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物の合成 |
| EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| KR100926399B1 (ko) | 2005-04-06 | 2009-11-12 | 아이알엠 엘엘씨 | 디아릴아민―함유 화합물 및 조성물, 및 스테로이드 호르몬핵 수용체의 조절제로서의 그들의 용도 |
| US7745641B2 (en) * | 2005-04-19 | 2010-06-29 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
| WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| CA2608476A1 (en) | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells |
| AR056191A1 (es) | 2005-08-23 | 2007-09-26 | Idenix Phatmaceuticals Inc | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae |
| WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| WO2007042298A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| US20070117775A1 (en) | 2005-10-31 | 2007-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and Methods For Treating Inflammatory Disorders |
| WO2007070872A1 (en) * | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| EP2108642A1 (en) | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
| MX2009004077A (es) | 2006-10-19 | 2009-05-05 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| JP5264759B2 (ja) | 2006-11-21 | 2013-08-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用 |
| JPWO2008081928A1 (ja) * | 2006-12-28 | 2010-04-30 | 大正製薬株式会社 | ピラゾロピリミジン化合物 |
| WO2008100715A1 (en) * | 2007-02-09 | 2008-08-21 | Astrazeneca Ab | Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613 |
| JP2010522174A (ja) | 2007-03-23 | 2010-07-01 | シェーリング コーポレイション | Ｈｃｖｎｓ３−プロテアーゼ阻害剤としてのヒドラジド−ペプチド |
| EP2162136A4 (en) | 2007-06-03 | 2012-02-15 | Univ Vanderbilt | GLUTAMATE METABOTROPIC POSITIVE RECEPTOR-BASED ALLOSTERIC-MODULATOR BENZAMIDE DERIVATIVES (MGLUR5) AND METHODS OF MAKING AND USING THEM |
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| JP2009067729A (ja) | 2007-09-14 | 2009-04-02 | Kyowa Hakko Kirin Co Ltd | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| CA2705303A1 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| WO2009080638A2 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| AU2009215430B2 (en) | 2008-02-22 | 2015-02-12 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| KR101773313B1 (ko) | 2008-04-16 | 2017-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| WO2009145856A1 (en) | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| EP2310381A1 (en) | 2008-06-13 | 2011-04-20 | Novartis AG | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer |
| WO2010015518A2 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EP3552607A3 (en) | 2008-12-08 | 2020-01-15 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| EP2443106A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| MX2012007154A (es) | 2009-12-17 | 2012-08-01 | Merck Sharp & Dohme | Aminopirimidinas como inhibidores de syk. |
| SG181857A1 (en) * | 2009-12-23 | 2012-07-30 | Takeda Pharmaceutical | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
-
2010
- 2010-12-17 SG SG2012045936A patent/SG181857A1/en unknown
- 2010-12-17 EP EP20198958.9A patent/EP3825316A1/en not_active Withdrawn
- 2010-12-17 MY MYPI2012002889A patent/MY159257A/en unknown
- 2010-12-17 GE GEAP201012794A patent/GEP20156243B/en unknown
- 2010-12-17 CN CN201080063801.2A patent/CN102753548B/zh active Active
- 2010-12-17 ME MEP-2015-125A patent/ME02186B/me unknown
- 2010-12-17 DK DK10800835.0T patent/DK2516434T3/en active
- 2010-12-17 PE PE2012000885A patent/PE20130188A1/es active IP Right Grant
- 2010-12-17 MA MA35044A patent/MA33909B1/fr unknown
- 2010-12-17 HR HRP20150878TT patent/HRP20150878T1/hr unknown
- 2010-12-17 UA UAA201207806A patent/UA107100C2/ru unknown
- 2010-12-17 MX MX2012007402A patent/MX2012007402A/es active IP Right Grant
- 2010-12-17 US US12/972,333 patent/US8440689B2/en active Active
- 2010-12-17 US US13/518,806 patent/US9181255B2/en active Active
- 2010-12-17 PH PH1/2012/501311A patent/PH12012501311A1/en unknown
- 2010-12-17 EP EP18200820.1A patent/EP3489236B1/en active Active
- 2010-12-17 AU AU2010333804A patent/AU2010333804B2/en active Active
- 2010-12-17 PT PT108008350T patent/PT2516434E/pt unknown
- 2010-12-17 EP EP14199188.5A patent/EP2902392B1/en active Active
- 2010-12-17 CA CA2786950A patent/CA2786950C/en active Active
- 2010-12-17 ES ES10800835.0T patent/ES2545616T3/es active Active
- 2010-12-17 WO PCT/US2010/061146 patent/WO2011079051A1/en not_active Ceased
- 2010-12-17 PL PL10800835T patent/PL2516434T3/pl unknown
- 2010-12-17 JP JP2012546092A patent/JP5658274B2/ja active Active
- 2010-12-17 HU HUE10800835A patent/HUE025177T2/en unknown
- 2010-12-17 EA EA201290555A patent/EA021568B1/ru unknown
- 2010-12-17 EP EP10800835.0A patent/EP2516434B1/en active Active
- 2010-12-17 SI SI201031001T patent/SI2516434T1/sl unknown
- 2010-12-17 NZ NZ60126710A patent/NZ601267A/en not_active IP Right Cessation
- 2010-12-17 RS RS20150544A patent/RS54180B1/sr unknown
- 2010-12-17 BR BR112012015651-9A patent/BR112012015651B1/pt not_active IP Right Cessation
- 2010-12-17 KR KR1020127019343A patent/KR101790255B1/ko active Active
- 2010-12-22 UY UY33151A patent/UY33151A/es not_active Application Discontinuation
- 2010-12-22 AR ARP100104923 patent/AR081797A1/es unknown
- 2010-12-22 JO JOP/2010/0471A patent/JO3108B1/ar active
- 2010-12-23 TW TW99145627A patent/TWI457339B/zh active
-
2012
- 2012-06-19 IL IL220509A patent/IL220509A/en active IP Right Grant
- 2012-06-21 TN TNP2012000316A patent/TN2012000316A1/en unknown
- 2012-06-25 DO DO2012000180A patent/DOP2012000180A/es unknown
- 2012-06-25 CL CL2012001745A patent/CL2012001745A1/es unknown
- 2012-07-19 CO CO12121953A patent/CO6592058A2/es active IP Right Grant
- 2012-07-19 ZA ZA2012/05428A patent/ZA201205428B/en unknown
- 2012-07-23 CR CR20120392A patent/CR20120392A/es unknown
- 2012-07-23 EC ECSP12012057 patent/ECSP12012057A/es unknown
-
2013
- 2013-05-02 US US13/886,032 patent/US9108970B2/en active Active
-
2014
- 2014-11-27 JP JP2014239677A patent/JP5968983B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-31 US US14/814,878 patent/US20150336964A1/en not_active Abandoned
- 2015-08-17 SM SM201500199T patent/SMT201500199B/xx unknown
- 2015-08-26 CY CY20151100745T patent/CY1116736T1/el unknown
-
2016
- 2016-07-06 JP JP2016133849A patent/JP6196710B2/ja active Active
-
2017
- 2017-08-18 JP JP2017158005A patent/JP2018009017A/ja active Pending
- 2017-08-21 US US15/681,953 patent/US20180141951A1/en not_active Abandoned
-
2018
- 2018-12-17 JP JP2018235779A patent/JP2019056000A/ja active Pending
-
2019
- 2019-06-21 US US16/449,123 patent/US20220306634A1/en not_active Abandoned
-
2020
- 2020-06-23 JP JP2020107416A patent/JP2020164537A/ja active Pending
-
2022
- 2022-05-20 JP JP2022083170A patent/JP2022110135A/ja active Pending
-
2023
- 2023-01-12 US US18/096,392 patent/US20230295171A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515729A5 (enExample) | ||
| JP6770127B2 (ja) | Ｂｔｋ阻害薬としての一級カルボキサミド類 | |
| AU2018374456B2 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| KR101851130B1 (ko) | Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클 | |
| ME02186B (me) | Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori | |
| JP5775070B2 (ja) | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 | |
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| JP2019535664A5 (enExample) | ||
| HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
| CN104603113B (zh) | 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途 | |
| JP2013512282A (ja) | 新規三環式化合物 | |
| JP2013500247A5 (enExample) | ||
| MX2013003913A (es) | Compuestos de furo [3, 2-d] pirimidina. | |
| TW201803871A (zh) | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 | |
| JP6663021B2 (ja) | 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用 | |
| US12466831B2 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
| CN102131807A (zh) | 吡唑并吡啶激酶抑制剂 | |
| RS56102B1 (sr) | Derivati pirimidina | |
| JP2016523911A5 (enExample) | ||
| KR20150063030A (ko) | 치환된 피리딘 아졸로피리미딘-5-(6h)-온 화합물 | |
| KR20140068020A (ko) | Btk 억제제 | |
| JP2014528482A5 (enExample) | ||
| JP2022539373A (ja) | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用 | |
| JP2020526549A5 (enExample) | ||
| JP2017518326A5 (enExample) |